Justia Patents Opinion Summaries

The matter concerns a patent covering methods for generating digital images using an external visual server, offloading intensive image processing from a client device to a server that generates, compresses, and transmits images back to the client for display. The patent’s claimed improvement over prior art is the complete transfer of visual processing to the external server, so that the client only handles user input and image decompression. Sony sought inter partes review of twelve claims in the patent, arguing they were obvious in light of prior art, particularly a patent (“Wiltshire”) that described a server-based gaming system transmitting compressed images to clients.Previously, the Patent Trial and Appeal Board (the Board) initially found the claims not unpatentable, concluding Wiltshire did not disclose “generating” images at the server as required by the claims. On Sony’s appeal, the United States Court of Appeals for the Federal Circuit vacated that decision, holding that Wiltshire did disclose generating new images at the server, especially since it referenced games such as Doom that require real-time image generation. The Federal Circuit remanded for further proceedings. On remand, the Board found that Wiltshire, in combination with another reference (“Saha”) disclosing MPEG compression, taught all claim limitations, including the necessary image compression and transmission steps, and held all challenged claims unpatentable as obvious.On appeal, the United States Court of Appeals for the Federal Circuit reviewed whether the Board had exceeded the scope of its mandate or lacked substantial evidence for its findings. The Federal Circuit held that the Board properly followed its mandate, did not improperly revisit issues, and that substantial evidence supported the Board’s finding that the prior art disclosed all elements of the challenged claims. The court affirmed the Board’s decision, holding the claims unpatentable as obvious. View "INTELLECTUAL PIXELS LIMITED v. SONY INTERACTIVE ENTERTAINMENT LLC " on Justia Law

The dispute centered on two patents owned by Wyeth that claim methods of treating non-small cell lung cancer (NSCLC) resistant to two specific drugs, gefitinib and erlotinib, by administering “irreversible” EGFR inhibitors. The patents require the daily administration of a “unit dosage” of an irreversible EGFR inhibitor that covalently binds to specific amino acids in the EGFR protein. The patent specifications list three example compounds, describe in vitro test results, and provide general dosage ranges. However, the specifications do not include any working examples of dosing regimens administered to human patients, nor do they explain how to reliably determine a therapeutically effective and safe dosage for such patients.In the United States District Court for the District of Delaware, Wyeth sued AstraZeneca for alleged infringement based on AstraZeneca’s marketing of an irreversible EGFR inhibitor. After a jury found in Wyeth’s favor, determining the asserted patent claims were not invalid and awarding damages, AstraZeneca renewed its motion for judgment as a matter of law (JMOL), arguing that the patents were invalid for lack of enablement. The district court granted JMOL, concluding that the patents did not provide sufficient guidance for a skilled artisan to determine a suitable daily unit dosage for patients without undue experimentation, especially given the evidence that some disclosed dosage ranges would be toxic in humans.The United States Court of Appeals for the Federal Circuit affirmed the district court’s judgment. The Federal Circuit held that the asserted claims were invalid for lack of enablement under 35 U.S.C. § 112(a). The court concluded that the patent specifications failed to teach skilled artisans how to determine, without undue experimentation, daily unit dosages that would be therapeutically effective and safe for patients across the full scope of the claimed compounds. View "WYETH LLC v. ASTRAZENECA PHARMACEUTICALS LP " on Justia Law

TrackTime, LLC owned two patents claiming methods and systems for navigating within multimedia files on a mobile device using a time-correlated transcript. The patents described creating a synchronization index that allows users to tap on text to play corresponding multimedia segments and to annotate and share transcripts. TrackTime sued Amazon.com Services LLC and Audible, Inc. for patent infringement in the United States District Court for the District of Delaware, asserting claims from both patents.In the District of Delaware, the court ruled on two sets of claims. For the ’978 patent, the court construed certain limitations as means-plus-function terms under 35 U.S.C. § 112(f) and found the claims indefinite due to insufficient structural disclosure in the specification, leading to a holding of invalidity. For the ’638 patent, a jury trial was held focusing on claim 9. The jury found claim 9 not infringed and invalid for anticipation, as well as for other grounds. TrackTime’s post-trial motions for judgment as a matter of law and for a new trial were denied. Final judgment was entered accordingly.The United States Court of Appeals for the Federal Circuit reviewed the case. For the ’978 patent, the court found that further analysis was needed regarding whether the “executable program code” limitations should be considered means-plus-function terms under § 112(f), especially in light of intervening precedent from Dyfan, LLC v. Target Corp. The court vacated the district court’s indefiniteness ruling and remanded for further proceedings. For the ’638 patent, the Federal Circuit affirmed the judgment of invalidity for anticipation, holding there was sufficient evidence for the jury to find claim 9 anticipated by LiveNote and affirming the denial of post-trial motions. The disposition was affirmed in part, vacated in part, and remanded. View "TRACKTIME, LLC v. AMAZON.COM SERVICES LLC " on Justia Law

Otsuka America Pharmaceutical and its subsidiary own a patent covering a method for treating pseudobulbar affect and emotional lability by administering dextromethorphan with quinidine. Their branded drug, Nuedexta, combines these substances in their salt forms. After the FDA approved Hetero Labs’ generic version, which uses identical salt forms and amounts, Hetero announced plans to launch its product. Otsuka responded by filing suit in the United States District Court for the District of Delaware, seeking a temporary restraining order and a preliminary injunction to block Hetero’s market entry.The District Court for the District of Delaware first issued a temporary restraining order, then granted a preliminary injunction, preventing Hetero from selling its generic drug. The court found Otsuka likely to succeed in proving patent infringement and determined that equitable factors favored the injunction. It also waived the requirement for Otsuka to post a bond pending appeal, citing strong equities in Otsuka’s favor.The United States Court of Appeals for the Federal Circuit reviewed the case. It affirmed the district court’s interpretation of the patent claim terms “dextromethorphan” and “quinidine” as including both the free base and salt forms administered to patients, rather than only the active moiety. This construction meant that Hetero’s generic product infringed the patent. The Federal Circuit also held that the district court acted within its discretion in granting the preliminary injunction. However, it vacated the district court’s waiver of the Rule 65(c) bond requirement, finding that such waivers are extremely rare in cases involving commercial activity, and remanded the issue for reconsideration. Thus, the preliminary injunction was affirmed but the bond waiver was vacated and remanded. View "OTSUKA AMERICA PHARMACEUTICAL, INC. v. HETERO LABS LIMITED " on Justia Law

Norwich Pharmaceuticals sought to market a generic version of Xifaxan, a drug invented by Salix Pharmaceuticals for treating irritable bowel syndrome with diarrhea and hepatic encephalopathy. Norwich submitted an Abbreviated New Drug Application (ANDA) to the FDA, identified as number 214369. Salix believed this ANDA infringed its patents and sued Norwich in the United States District Court for the District of Delaware. That court found Norwich’s ANDA infringed Salix’s patents related to hepatic encephalopathy, while the patents for irritable bowel syndrome were invalid as obvious. The court’s final judgment barred FDA approval of Norwich’s ’369 ANDA until Salix’s hepatic encephalopathy patents expired in October 2029.Following the judgment, Norwich amended its ’369 ANDA to remove the indication for hepatic encephalopathy and requested the Delaware District Court modify its judgment to allow immediate FDA approval of the amended ANDA. The court denied this motion, reasoning that Norwich could not change its ANDA after final judgment to circumvent the prior ruling. Norwich appealed to the United States Court of Appeals for the Federal Circuit, which agreed the judgment restricted approval of the entire ANDA, including non-infringing indications, until 2029, and affirmed the Delaware District Court’s decision.After the FDA declined to grant final approval of Norwich’s amended ANDA, instead issuing only tentative approval, Norwich sued in the United States District Court for the District of Columbia, arguing the FDA acted arbitrarily and capriciously. The court granted summary judgment to the FDA and Salix. On appeal, the United States Court of Appeals for the District of Columbia Circuit held that the Delaware District Court’s judgment applied to Norwich’s ANDA as amended, so the FDA correctly delayed final approval until October 2029. The appellate court affirmed the district court’s judgment. View "Norwich Pharmaceuticals, Inc. v. Kennedy" on Justia Law

Enanta Pharmaceuticals owned a patent directed to certain chemical compounds and methods for inhibiting coronavirus replication. The patent claimed priority to an earlier provisional application filed in July 2020. In the original provisional application, the relevant chemical group was described as containing two to twelve carbon atoms, while in the later patent, the range was changed to include one to twelve carbon atoms. Before the non-provisional patent was filed, Pfizer publicly disclosed a compound that fell within the scope of Enanta’s later patent claims.Enanta filed suit in the United States District Court for the District of Massachusetts, asserting that Pfizer’s product infringed its patent. Pfizer countered that the patent was invalid because its public disclosure anticipated the patent claims, and argued that Enanta’s patent could not claim priority to the earlier provisional application since the specific chemical group was not adequately supported in the provisional filing. The district court granted summary judgment in Pfizer’s favor, concluding that the change from two to one carbon atoms was not a correctable typographical error, and that the patent could not claim the earlier priority date.On appeal, the United States Court of Appeals for the Federal Circuit reviewed the district court’s decision de novo. The appellate court held that the provisional application did not provide written description support for the later patent’s claims, specifically the inclusion of the one-carbon group, and thus the patent was not entitled to the earlier priority date. As a result, Pfizer’s disclosure anticipated all claims of Enanta’s patent, rendering them invalid. The Federal Circuit affirmed the district court’s grant of summary judgment. View "ENANTA PHARMACEUTICALS, INC. v. PFIZER INC. " on Justia Law

Ironburg Inventions Ltd. owns a patent for a video game controller featuring additional, resilient controls on the back of the device. Ironburg alleged that Valve Corporation’s Steam Controller infringed several claims of this patent. Valve responded by filing an inter partes review (IPR) petition in 2016 challenging the patent, and later amended its invalidity contentions in district court proceedings to include new grounds based on prior art references that had been asserted by a third party, Collective Minds Gaming Co. Ltd., in a separate IPR.The United States District Court for the Western District of Washington granted Ironburg’s motion for IPR estoppel under 35 U.S.C. § 315(e)(2), barring Valve from asserting two invalidity grounds—one based on the Kotkin reference and another combining Willner, Koji, and Raymond—finding they could have been discovered by a skilled searcher conducting a diligent search. After a jury verdict for Ironburg and an initial appeal, the United States Court of Appeals for the Federal Circuit vacated and remanded, instructing the district court to place the burden on Ironburg and to evaluate whether the grounds were reasonably discoverable.On remand, the district court again estopped Valve from raising both grounds. The United States Court of Appeals for the Federal Circuit reviewed the evidence and found that the district court erred. Specifically, the district court relied on insufficient evidence to estop the Kotkin ground, as the search results from Valve’s agent included thousands of references without further narrowing. For the Willner-Koji-Raymond ground, the district court failed to properly account for hindsight bias in the evidence presented. The Federal Circuit reversed the district court’s estoppel rulings and remanded for proceedings consistent with its opinion, instructing the district court to reconsider the invalidity of the patent in light of both grounds. View "IRONBURG INVENTIONS LTD. v. VALVE CORPORATION " on Justia Law

The dispute centers on three patents owned by the appellant, which describe a method for displaying information to facilitate the return of lost or stolen computers. The patented method involves powering on a computer and automatically displaying a screen with return information, either before or alongside the lock screen, and includes the ability to remotely initiate or change the displayed information without assistance from a user with the computer. The appellant alleged that certain devices sold by LG Electronics, featuring Google or Microsoft’s “Find My Device” software, infringed these patents.Following the appellant’s lawsuit in the United States District Court for the Western District of Texas, Google and Microsoft initiated six inter partes review (IPR) proceedings before the United States Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB), contesting the validity of the patents based on prior art. The PTAB instituted review despite the appellant’s arguments referencing a parallel district court action and concerns about duplicative proceedings. LG, named as a real party in interest, filed a “Sotera stipulation,” agreeing not to pursue in district court any grounds raised in the IPRs, which the PTAB considered in its decision to institute review.The United States Court of Appeals for the Federal Circuit reviewed the PTAB’s final written decisions, which found all challenged claims unpatentable. The Federal Circuit held that it lacked jurisdiction to review challenges tied to the PTAB’s institution decision, specifically regarding the impact of LG’s violation of the Sotera stipulation. On the merits, the court affirmed the PTAB’s construction of the “without assistance” claim limitation, finding no error and concluding that the prior art disclosed the disputed method. The court also determined that the PTAB’s analysis of secondary considerations of non-obviousness was supported by substantial evidence. The court dismissed the appeal in part and affirmed in part, awarding costs against the appellant. View "HAFEMAN v. GOOGLE LLC " on Justia Law

Amarin Pharma, Inc. developed and marketed Vascepa, a drug containing icosapent ethyl. Initially, the Food and Drug Administration (FDA) approved Vascepa for treating severe hypertriglyceridemia (the SH indication). Later, the FDA approved a new use: reducing cardiovascular risk in certain patients (the CV indication), for which Amarin held two method-of-use patents. Hikma Pharmaceuticals USA Inc., a generic manufacturer, sought to market a generic icosapent ethyl. After Amarin’s SH-indication patents were invalidated by a district court, Hikma pursued FDA approval for a “skinny label” generic, carving out the patented CV indication. The FDA approved Hikma’s application with the label limited to the SH indication.Amarin sued Hikma in the United States District Court for the District of Delaware, alleging that Hikma actively induced infringement of Amarin’s CV-indication patents. Amarin argued that various statements in Hikma’s skinny label, patient information leaflet, website, and press releases encouraged infringement. The District Court granted Hikma’s motion to dismiss, finding that the statements did not constitute active encouragement of infringement. The United States Court of Appeals for the Federal Circuit reversed, holding it plausible that a physician could read Hikma’s statements as instructions or encouragement to prescribe the drug for the patented use.The Supreme Court of the United States reviewed the case and held that Amarin failed to state a claim for active inducement under 35 U.S.C. §271(b). The Court clarified that liability requires affirmative “active steps” to encourage infringement, not merely statements that could be read as encouragement. The Court found Hikma’s statements either reflected legal compliance or ordinary industry practice, or were too vague or passive to plausibly constitute active inducement. The Supreme Court reversed the Federal Circuit’s judgment and remanded for further proceedings. View "Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc." on Justia Law

A dispute arose between two companies over patents related to wireless communications for building automation systems. The plaintiff alleged that the defendant’s smart thermostat products infringed four patents, which addressed improvements in wireless network architecture, power and bandwidth usage, and data redundancy within building control systems. At trial, a jury found that the defendant had infringed at least one of the asserted patents (without specifying which), determined that the claims of one patent were not limited to well-understood or routine technology, found another patent’s claims invalid, and awarded the plaintiff lump sum damages.In the United States District Court for the Eastern District of Texas, the defendant moved to dismiss based on patent ineligibility under 35 U.S.C. § 101, but the court denied these motions for the patents at issue, except for one where factual disputes precluded summary judgment. The court also denied the defendant’s post-trial motions, including challenges to the verdict form, jury instructions related to patent eligibility, and motions to exclude expert testimony. The plaintiff, in turn, appealed the district court’s limitation on prejudgment interest.The United States Court of Appeals for the Federal Circuit reviewed the case and determined that the district court’s verdict form, which combined all asserted patents into a single infringement question, violated the defendant’s right to a unanimous verdict. The appellate court vacated both the infringement and damages judgments and remanded for a new trial on those issues. The court also vacated and remanded the § 101 eligibility determination for one patent, requiring further proceedings under the Alice framework. However, the court affirmed the district court’s findings that the asserted claims of two other patents were not directed to abstract ideas and that substantial evidence supported the jury’s verdict of infringement on one patent. Remaining evidentiary and interest issues were dismissed as moot. View "OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC " on Justia Law